Arecor Therapeutics PLC ARECOR 2022 ANNUAL REPORT AND NOTICE OF AGM (4731Y)
May 04 2023 - 11:00AM
UK Regulatory
TIDMAREC
RNS Number : 4731Y
Arecor Therapeutics PLC
04 May 2023
POSTING OF ARECOR 2022 ANNUAL REPORT AND NOTICE OF AGM
Cambridge, UK, 4 May 2023. Arecor Therapeutics plc (AIM: AREC),
the biopharmaceutical company advancing today's therapies to enable
healthier lives, announces that it has today published and posted
to shareholders the Annual Report and Accounts for the year ended
31 December 2022 and Notice of the Annual General Meeting ("AGM")
which will be held at Covington & Burling LLP, 22 Bishopsgate,
London EC2N 4BQ , on 9 June 2023 at 9.30 a.m. (BST).
The Annual Report and Accounts and notice of AGM are also
available to view on, and download from, the Company's website at
www.arecor.com/investor-centre/shareholder-information/
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM), we are developing an internal portfolio of proprietary
products in diabetes and other indications, as well as working with
leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat(TM) platform is supported by an
extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSSSDFDLEDSEII
(END) Dow Jones Newswires
May 04, 2023 11:00 ET (15:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024